New drug aims to limit heart damage after major attack

NCT ID NCT07362446

Recruiting now Disease control Sponsor: Nyrada Pty Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 6 times

Summary

This study tests a medicine called Xolatryp in adults who have had a severe heart attack (STEMI) and are getting a procedure to open blocked arteries. Participants receive either a single 6-hour infusion of Xolatryp or a placebo, and their heart health is monitored for 30 days. The goal is to see if Xolatryp is safe and helps the heart recover better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMI are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia ischemia reperfusion injury myocardial infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMI MYOCARDIAL INFARCTION REPERFUSION INJURY STEMI (ST ELEVATION MI)

Contacts and locations

Locations

Liverpool Hospital
NOT_YET_RECRUITING

Liverpool, New South Wales, 2170, Australia
Nepean Hospital
RECRUITING

Kingswood, New South Wales, 2747, Australia
Northern Health
NOT_YET_RECRUITING

Epping, Victoria, 3076, Australia
Royal Adelaide Hospital
NOT_YET_RECRUITING

Adelaide, South Australia, 5000, Australia
Royal Perth Hospital
NOT_YET_RECRUITING

Perth, Western Australia, 6000, Australia
Sir Charles Gairdner Hospital
RECRUITING

Nedlands, Western Australia, 6009, Australia
Sunshine Hospital
NOT_YET_RECRUITING

Saint Albans, Victoria, 3021, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.